Pernicious anemia has recently been recognized as a risk factor for osteoporosis and fractures. Although vitamin B12 is important for osteoblast function, the effect of vitamin B,z replacement in states of vitamin 8,~ deficiency on bone density and fracture incidence is not known. We report 2-year follow-up data from a patient with severe osteoporosis, multiple vertebral compression fractures, and pernicious anemia who exhibited a dramatic response to treatment with vitamin B12 and cyclic etidronate. Serial bone density measurements demonstrated a 15% and 17% increase in the lumbar and greater trochanter regions, respectively, and a 79% increase in the femoral neck region over the 2-year follow-up period. In addition to normalization of bone density compared with age-matched controls, no subsequent vertebral fractures were noted in the 2-year period following initiation of vitamin B12 and etidronate therapy. This case demonstrates that osteoporosis associated with pernicious anemia may be markedly improved by vitamin 8,~ replacement and cyclic etidronate therapy.
P

ERNICIOUS
ANEMIA has been identified as a risk factor for osteoporosis* and proximal femur, distal forearm, and vertebral fractures.? Vitamin Blz is thought to be important for osteoblast activity. and treatment of pernicious anemia with vitamin Blz increases serum markers of bone formation?
However, the effect of vitamin B12 replacement on bone density and fracture rate over time in patients with pernicious anemia and osteoporosis has not been studied. Bisphosphonates administered in a cyclic regimen have been used with success to treat postmenopausal osteoporosis; i,5 however, their efficacy in treating osteoporosis due to other causes is not known. Here we report data from a 2-year observation period of a man with pernicious anemia accompanied by severe osteoporosis and multiple vertebral fractures in whom marked improvement in bone density and reduction Table 1 ). The bone density in both the lumbar spine and proximal femur had increased markedly and was normal for age.
DISCUSSION
There are no published reports describing the effect on bone disease of vitamin B,l replacement or other therapies in patients with osteoporosis due to pernicious anemia or other causes of vitamin B13 deficiency. This patient displayed a marked improvement in bone density with the combination of vitamin B,z and cyclic ctidronate therapy.
The comparison of bone density measurements must be interpreted with an understanding of the different densitometry systems. A comparison of the two densitomctry techniques used in this report (DPA and DEXA, Lunar) at both lumbar vertebrae and the femoral neck has shown a high Metabol/sm, Vol43, No 4 (April), 1994: pp 468-469 tTwo-year follow-up measurements were obtained using DEXA (Lunar DPX system).
etidronate, it is unclear whether a single agent or a combination of agents acting synergistically was responsible for the reversal of osteoporosis.
Etidronate is thought to act primarily by decreasing bone resorption. Cyclic administration of etidronate has been associated with modest increases in bone density in patients with postmenopausal osteoporosis.4J
Dramatic increases in bone mineral density, as seen in this patient, have not been reported as a result of etidronate therapy alone. Vitamin B12 appears to be important for osteoblast activity and bone formation3 Whether vitamin Blz alone could be responsible for the improvement seen in this patient is unknown. Theoretically, by administering these two agents simultaneously, the rate of bone resorption would be decreased by etidronate while at the same time vitamin B12 replacement would allow bone formation to proceed, resulting in a net increase in bone density above what might be expected from vitamin B,? alone.
SDPX 'data were compared with DP3 data at L2-4 by applying the following equation: DPX = 1.072 DP3 -0.095.6 correlation (r > .97).h In fact, the DEXA measurements tend to be slightly lower than the DPA measurements6 Taking this into account, the increase in bone density seen in this patient was more likely to have been underestimated rather than overestimated. Therefore, it is not possible to explain the improvement in bone density in this patient by differences in densitometry technique. Indeed, it is most likely that the therapy instituted in this patient was responsible for the dramatic improvement in bone density. Since this patient received both vitamin B12 and cyclic
The dramatic improvement seen in this patient suggests that osteoporosis due to vitamin B12 deficiency may be reversible and easily treated. Vitamin Bt2 deficiency is a common (and commonly unrecognized) disorder, with a prevalence of up to 10% in the elderly population7 Vitamin Btz deficiency often accompanies atrophic gastritis, and the prevalence of atrophic gastritis in the elderly population is approximately 3O%.8 Vitamin B12 deficiency may also play a role in the osteoporosis that commonly develops following gastrectomy and gastric bypass procedures.9,t0 Whether treatment with vitamin B12 replacement.
either alone or in combination with cyclic etidronate, will be as effective a treatment for osteoporosis in other patients with vitamin B12 deficiency is a question that warrants investigation.
